The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease

Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (DRD2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsibl...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders 2008-03, Vol.23 (4), p.599-602
Main Authors: Paus, Sebastian, Grünewald, Anne, Klein, Christine, Knapp, Michael, Zimprich, Alexander, Janetzky, Bernd, Möller, Jens C., Klockgether, Thomas, Wüllner, Ullrich
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dopamine Agonists - therapeutic use
DRD2
Female
Genotype
German Competence Network on PD
Humans
levodopa
Levodopa - therapeutic use
Male
Medical sciences
Middle Aged
Neurology
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson's disease
pharmacogenetics
Polymorphism, Genetic - genetics
Receptors, Dopamine D2 - genetics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (DRD2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsible for demand of dopaminergic medication, measured in total dopaminergic load per year of disease, in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Regression analysis yielded no significant differences between the TaqIA genotypes. We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD. We propose a practicable system of measuring dopaminergic treatment for future pharmacogenetic studies in PD. © 2007 Movement Disorder Society
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.21901